Table1 Baseline clinical charateristics of the two groups and the comparisons of baseline blood lipid profiles and lipoprotein particles between them
From: Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
Variable | PCSK9i + statins (n = 54) | Statins (n = 45) |
|---|---|---|
Age (years), mean ± SD | 60.6 ± 10.1 | 58.6 ± 10.6 |
Men, n (%) | 34(63.0%) | 30(66.7%) |
Hypertension, n (%) | 32(59.3%) | 26(57.8%) |
Diabetes, n (%) | 15(27.8%) | 10(22.2%) |
Stroke history, n (%) | 6(11.1%) | 5(11.1%) |
Dislipidemia, n (%) | 25(46.3%) | 20(44.4%) |
MI history, n (%) | 11(20.1%) | 10(22.2%) |
Prior PCI or CABG, n (%) | 20(37.0%) | 18(40.0%) |
Family history of CAD, n (%) | 17(31.5%) | 13(28.9%) |
Smoking, n (%) | 22(41.1%) | 23(51.1%) |
Drinking, n (%) | 20(37.0%) | 16(35.6%) |
BMI (kg/m2), mean ± SD | 26 ± 5.0 | 27 ± 5.4 |
High waist circumference (women > 88 cm, men > 102 cm), n(%) | 14(25.9%) | 13(28.9%) |
Statin use, n (%) | 21(38.9%) | 17(37.7%) |
ACS type, n (%) | ||
 STEMI | 10(18.5%) | 12(26.7%) |
 NSTEMI | 24(44.4%) | 20(44.4%) |
 UAP | 20(37.0%) | 13(28.9%) |
Total cholesterol (mg/dl), mean ± SD | 214.2 ± 42.4 | 189.7 ± 36.5 |
LDL-C (mg/dl), mean ± SD | 123.7 ± 32.3 | 103.7 ± 28.1 |
IDL-C (mg/dl), mean ± SD | 15.5 ± 9.1 | 13.6 ± 7.6 |
VLDL-C (mg/dl), mean ± SD | 31.9 ± 17.9 | 25.3 ± 15.5 |
HDL-C (mg/dl), mean ± SD | 43.9 ± 7.8 | 44.3 ± 9.4 |
Lp(a) (nmol/l), median (Q1, Q3) | 73.1(13.7,102.3) | 32.7(8.2,49.1) |
ApoB (mg/dl), mean ± SD | 108.7 ± 24.2 | 93.0 ± 20.8 |
LDL-P total (nmol/l), mean ± SD | 1573.9 ± 375.3 | 1317.8 ± 337.8 |
VLDL-P (nmol/l), mean ± SD | 237.5 ± 106.0 | 182.8 ± 89.2 |
IDL-P (nmol/l), mean ± SD | 91.0 ± 47.7 | 88.6 ± 43.3 |